NERV.US Minerva Neurosciences Inc

Healthcare Biotechnology USA Stocks
2.30 USD
Close of Nov 15, 2026
1.96 8.80
Market cap
USD 115M
P/E
-
P/B
2.68x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NERV.US undervalued?

Graham number

The Graham number of Minerva Neurosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Minerva Neurosciences Inc fundamental analysis

No fundamental analysis for Minerva Neurosciences Inc yet.

Minerva Neurosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Full company profile